<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04939376</url>
  </required_header>
  <id_info>
    <org_study_id>Uterine lesions and ICSI</org_study_id>
    <nct_id>NCT04939376</nct_id>
  </id_info>
  <brief_title>Uterine Lesions and Their Association to Invitro Fertilization(IVF) or Intracytoplasmic Sperm Injection(ICSI) Outcome</brief_title>
  <official_title>Association Between Uterine , Intracavitary , Cervical and Cervical Canal Lesions With in Vitro Fertilization/Intracytoplasmic Sperm Injection(IVF/ICSI) Outcome.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assiut University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assiut University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      1. To study the effect of uterine wall , intracavitary , cervical as well as cervical canal&#xD;
           lesion on the outcome of IVF/ICSI cycle.&#xD;
&#xD;
        2. To establish a score for prediction of IVF/ICSI cycle success .&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      IVF is one of the most successful treatment of fertility, (1) however, several IVF cycles&#xD;
      fail to achieve pregnancy (2).failure defined as three or more failed attempts of ICSI (3).&#xD;
      Implantation failure is a complex in nature, may be due to structural or functional causes&#xD;
      (3, 4).&#xD;
&#xD;
      that previously undiagnosed, misinterpreted initial diagnoses, or subtle newly added&#xD;
      intrauterine abnormalities may be a significant cause of IVF failure (5, 6), studies say that&#xD;
      intra-uterine pathologies represent 40-50 % of causes of ICSI failure (7, 8), hysteroscopic&#xD;
      removal of endometrial polyps, submucous fibroids, uterine septum, or intrauterine adhesions&#xD;
      could increase the pregnancy rate (9). so, Evaluation of the uterine cavity may become a&#xD;
      routine investigation before assisted reproductive technology(ART) procedures (10).&#xD;
&#xD;
      In this study, we evaluate the relationship between the different uterine and cervical&#xD;
      pathologies and decreased live birth rate.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">July 1, 2021</start_date>
  <completion_date type="Anticipated">April 1, 2024</completion_date>
  <primary_completion_date type="Anticipated">March 1, 2024</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Pregnancy rate</measure>
    <time_frame>Baseline</time_frame>
    <description>Pregnancy rate with IVF/ICSI with uterine lesions</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">122</enrollment>
  <condition>IVF</condition>
  <arm_group>
    <arm_group_label>Group A</arm_group_label>
    <description>Women with hysteroscopically or ultrasonographic detected uterine anomalies(adenomyosis,fibroid) intracavitary lesions ( like polyp, adhesion or septum) and those with detected endometrial abnormalities (like hypervascularization,pale endometrium) ,cervical lesion and cervical canal lesion or pelvic lesion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B</arm_group_label>
    <description>Matched women (eg. Age,parity, BMI, ovarian reserveâ€¦.) with no uterine or ovarian abnormalities assessed by hysteroscopy or ultrasonography.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>IVF</intervention_name>
    <description>In vitro fertilization</description>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_label>Group B</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Women between 18 and 38 years old.&#xD;
&#xD;
          -  An indication for IVF/ICSI..&#xD;
&#xD;
          -  Women with BMI between 18.5 : 29.9 .&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Women between 18 and 38 years old.&#xD;
&#xD;
               -  An indication for IVF/ICSI..&#xD;
&#xD;
               -  Women with BMI between 18.5 : 29.9 .&#xD;
&#xD;
               -  Women with normal antimullerian hormone(AMH), antral follicle count(AFC) (good&#xD;
                  responders).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Refusal to join the study.&#xD;
&#xD;
          -  Women with age less than 18 and more than 38 .&#xD;
&#xD;
          -  Women with BMI less than 18.5 and more than 30 .&#xD;
&#xD;
          -  Untreated tubal hydrosalpinges.&#xD;
&#xD;
          -  Poor responders as assessed by AFC 4 or less ,AMH O.8 ng/dl (nice 2013).&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>38 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Momen Kamel, Prof.dr</last_name>
    <role>Study Director</role>
    <affiliation>Assiut University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Khaled Mostafa, Rsedent.dr</last_name>
    <phone>0201140465869</phone>
    <email>khaledmostafa849@yahoo.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Momen Kamel, Prof.dr</last_name>
    <phone>0201000328901</phone>
    <email>Momen_k2000@yahoo.com</email>
  </overall_contact_backup>
  <reference>
    <citation>Rai R, Regan L. Recurrent miscarriage. Lancet. 2006 Aug 12;368(9535):601-11. Review.</citation>
    <PMID>16905025</PMID>
  </reference>
  <reference>
    <citation>Dicker D, Ashkenazi J, Feldberg D, Farhi J, Shalev J, Ben-Rafael Z. The value of repeat hysteroscopic evaluation in patients with failed in vitro fertilization transfer cycles. Fertil Steril. 1992 Oct;58(4):833-5.</citation>
    <PMID>1426335</PMID>
  </reference>
  <reference>
    <citation>Levi Setti PE, Colombo GV, Savasi V, Bulletti C, Albani E, Ferrazzi E. Implantation failure in assisted reproduction technology and a critical approach to treatment. Ann N Y Acad Sci. 2004 Dec;1034:184-99. Review.</citation>
    <PMID>15731311</PMID>
  </reference>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>June 17, 2021</study_first_submitted>
  <study_first_submitted_qc>June 17, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 25, 2021</study_first_posted>
  <last_update_submitted>June 26, 2021</last_update_submitted>
  <last_update_submitted_qc>June 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 30, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Assiut University</investigator_affiliation>
    <investigator_full_name>Khaled Mostafa Ahmed</investigator_full_name>
    <investigator_title>doctor</investigator_title>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

